104 related articles for article (PubMed ID: 16945323)
1. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes.
Dueñas-Romero AM; Loiseau PM; Saint-Pierre-Chazalet M
Biochim Biophys Acta; 2007 Feb; 1768(2):246-52. PubMed ID: 16945323
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of interaction of sitamaquine with Leishmania donovani.
Coimbra ES; Libong D; Cojean S; Saint-Pierre-Chazalet M; Solgadi A; Le Moyec L; Duenas-Romero AM; Chaminade P; Loiseau PM
J Antimicrob Chemother; 2010 Dec; 65(12):2548-55. PubMed ID: 20956354
[TBL] [Abstract][Full Text] [Related]
3. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani.
Bories C; Cojean S; Huteau F; Loiseau PM
Biomed Pharmacother; 2008 Mar; 62(3):164-7. PubMed ID: 18249083
[TBL] [Abstract][Full Text] [Related]
4. Sitamaquine-resistance in Leishmania donovani affects drug accumulation and lipid metabolism.
Imbert L; Cojean S; Libong D; Chaminade P; Loiseau PM
Biomed Pharmacother; 2014 Sep; 68(7):893-7. PubMed ID: 25201056
[TBL] [Abstract][Full Text] [Related]
5. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.
Rakotomanga M; Saint-Pierre-Chazalet M; Loiseau PM
Antimicrob Agents Chemother; 2005 Jul; 49(7):2677-86. PubMed ID: 15980336
[TBL] [Abstract][Full Text] [Related]
6. Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance.
Loiseau PM; Cojean S; Schrével J
Parasite; 2011 May; 18(2):115-9. PubMed ID: 21678786
[TBL] [Abstract][Full Text] [Related]
7. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
Wasunna MK; Rashid JR; Mbui J; Kirigi G; Kinoti D; Lodenyo H; Felton JM; Sabin AJ; Albert MJ; Horton J
Am J Trop Med Hyg; 2005 Nov; 73(5):871-6. PubMed ID: 16282296
[TBL] [Abstract][Full Text] [Related]
8. Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine.
Kulshrestha A; Singh R; Kumar D; Negi NS; Salotra P
Antimicrob Agents Chemother; 2011 Jun; 55(6):2916-21. PubMed ID: 21464251
[TBL] [Abstract][Full Text] [Related]
9. In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani.
Seifert K; Munday J; Syeda T; Croft SL
J Antimicrob Chemother; 2011 Apr; 66(4):850-4. PubMed ID: 21393188
[TBL] [Abstract][Full Text] [Related]
10. Complex Interplay between Sphingolipid and Sterol Metabolism Revealed by Perturbations to the Leishmania Metabolome Caused by Miltefosine.
Armitage EG; Alqaisi AQI; Godzien J; Peña I; Mbekeani AJ; Alonso-Herranz V; López-Gonzálvez Á; Martín J; Gabarro R; Denny PW; Barrett MP; Barbas C
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463533
[TBL] [Abstract][Full Text] [Related]
11. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis.
Garnier T; Brown MB; Lawrence MJ; Croft SL
J Pharm Pharmacol; 2006 Aug; 58(8):1043-54. PubMed ID: 16872550
[TBL] [Abstract][Full Text] [Related]
12. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes.
López-Martín C; Pérez-Victoria JM; Carvalho L; Castanys S; Gamarro F
Antimicrob Agents Chemother; 2008 Nov; 52(11):4030-6. PubMed ID: 18794384
[TBL] [Abstract][Full Text] [Related]
13. The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase.
Carvalho L; Luque-Ortega JR; López-Martín C; Castanys S; Rivas L; Gamarro F
Antimicrob Agents Chemother; 2011 Sep; 55(9):4204-10. PubMed ID: 21670183
[TBL] [Abstract][Full Text] [Related]
14. Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani.
Kothari H; Kumar P; Sundar S; Singh N
Parasitol Int; 2007 Mar; 56(1):77-80. PubMed ID: 17169604
[TBL] [Abstract][Full Text] [Related]
15. In vitro antileishmanial activity of fluoro-artemisinin derivatives against Leishmania donovani.
Chollet C; Crousse B; Bories C; Bonnet-Delpon D; Loiseau PM
Biomed Pharmacother; 2008 Sep; 62(7):462-5. PubMed ID: 18538529
[TBL] [Abstract][Full Text] [Related]
16. Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania.
Pérez-Victoria JM; Bavchvarov BI; Torrecillas IR; Martínez-García M; López-Martín C; Campillo M; Castanys S; Gamarro F
Antimicrob Agents Chemother; 2011 Aug; 55(8):3838-44. PubMed ID: 21646479
[TBL] [Abstract][Full Text] [Related]
17. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
Paila YD; Saha B; Chattopadhyay A
Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
[TBL] [Abstract][Full Text] [Related]
19. Antiparasitic activity of a triphenyl tin complex against Leishmania donovani.
Raychaudhury B; Banerjee S; Gupta S; Singh RV; Datta SC
Acta Trop; 2005 Jul; 95(1):1-8. PubMed ID: 15896700
[TBL] [Abstract][Full Text] [Related]
20. Triazino indole-quinoline hybrid: a novel approach to antileishmanial agents.
Sharma R; Pandey AK; Shivahare R; Srivastava K; Gupta S; Chauhan PM
Bioorg Med Chem Lett; 2014 Jan; 24(1):298-301. PubMed ID: 24314395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
